TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19080647

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (40-45 Gy, 5 times a week)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Chemotherapy only (Control Group II)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for resectable patients)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Chemotherapy only (Control Group II for resectable patients)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy (for un-resectable patients)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Chemotherapy only (Control Group II for un-resectable patients)
Number of subjects: 83
Study: 20043468

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg daily
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Eltrombopag 30 mg daily
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Eltrombopag (any dose)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Eltrombopag (extension study)
Number of subjects: 231
Study: 14760040

Group type: COMPARATOR
Intervention: Health screening and health discussions in general practice (not quantified in the abstract)
Number of subjects: 18
Study: 11327054

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 48
Study: 9158975

Group type: EXPERIMENTAL
Intervention: McMaster Teen Program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional didactic sex education program
Number of subjects: 21
Study: 8108576

Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg a day for 3 consecutive days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Clodronate (300 mg a day for 3 consecutive days)
Number of subjects: 14
Study: 3501156

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 31201036

Group type: EXPERIMENTAL
Intervention: Locator attachments
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bars
Number of subjects: 50
Study: 31491758

Group type: EXPERIMENTAL
Intervention: Topical vancomycin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29224823

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (20 mg/m2)
Number of subjects: 92
Study: 26315857

Group type: EXPERIMENTAL
Intervention: FamCope intervention (nurse-led family-coping-orientated palliative home care intervention)
Number of subjects: 0
Study: 24337348

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) of renal masses
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) of renal masses in patients with newly diagnosed renal cell carcinoma
Number of subjects: 137
Study: 23166425

Group type: EXPERIMENTAL
Intervention: 200 IU/day nasal salmon calcitonin and a home exercise program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Home exercise program
Number of subjects: 50
Study: 19541917

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RT)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intensive comparison therapy (ICT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 127
Study: 17503984

Group type: EXPERIMENTAL
Intervention: Paroxetine (60 mg/day)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Venlafaxine (up to 300 mg/day)
Number of subjects: 91
Study: 15072661

Group type: EXPERIMENTAL
Intervention: Stepwise band-filling during 6 monthly ambulant visits
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bolus-filling 4 weeks postoperatively
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bolus-filling
Number of subjects: 40
Study: 11743529

Group type: EXPERIMENTAL
Intervention: Continuous cryotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 70
Study: 9376095

Group type: EXPERIMENTAL
Intervention: HIV/AIDS prevention workshop (4 sessions of 3 hours each)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 394
Study: 7701278

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3610509

Group type: EXPERIMENTAL
Intervention: Benzydamine mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 0
Study: 29738877

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) 2 g orally 2 h preoperatively and two doses of 1 g TXA postoperatively
Number of subjects: 117

Group type: COMPARATOR
Intervention: Topical tranexamic acid (TXA) 3 g administered in the operating room
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Oral group
Number of subjects: 117

Group type: COMPARATOR
Intervention: Topical group
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 117
Study: 26890957

Group type: EXPERIMENTAL
Intervention: Beam-like rods (BR)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Circular rods (CR)
Number of subjects: 129
Study: 25024234

Group type: EXPERIMENTAL
Intervention: Hatha yoga intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Stretching-strengthening control
Number of subjects: 118
Study: 22647314

Group type: EXPERIMENTAL
Intervention: Training in manualized CBT
Number of subjects: 162

Group type: COMPARATOR
Intervention: No specific training (Control)
Number of subjects: 162
Study: 21246842

Group type: EXPERIMENTAL
Intervention: Acupoint injection of rHuEpo at Zusanli (ST 36) and Shenshu (BL 23), 3 times a week for 2 months.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Subcutaneous injection of rHuEpo, 3 times a week for 2 months (Control group).
Number of subjects: 38
Study: 18411016

Group type: EXPERIMENTAL
Intervention: Health behaviors, psychological variables, and QOL assessment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Physical activity and CD4 cell count
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Smoking and depressive symptoms
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Education, physical activity, and depressive symptoms
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Coping styles
Number of subjects: 97
Study: 16106314

Group type: EXPERIMENTAL
Intervention: Nebulizer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Commercially available spacer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Homemade non-valved spacer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dry powder inhaler
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12693586

Group type: EXPERIMENTAL
Intervention: Artecom (group A)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Artesunate-mefloquine (group B)
Number of subjects: 352
Study: 10408542

Group type: EXPERIMENTAL
Intervention: High-dose transdermal 17beta-estradiol (four skin patches each releasing 0.1 mg of estradiol daily, replaced every 2 to 3 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7579128

Group type: EXPERIMENTAL
Intervention: Histamine (0.5 microgram kg‐1 min‐1 for 20 min) after pretreatment with placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mepyramine (histamine‐H1‐receptor antagonist) pretreatment
Number of subjects: 20
Study: 2123881

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate and human menopausal gonadotrophin (CC/HMG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Human menopausal gonadotrophin (HMG) alone
Number of subjects: 41
Study: 7438381

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1239
Study: 31678062

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sleeve gastrectomy
Number of subjects: 109
Study: 28097355

Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 1023
Study: 26027245

Group type: EXPERIMENTAL
Intervention: Etoricoxib (ET) 90 mg continuously every day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Etoricoxib (ET) 90 mg intermittently 1‐3 times weekly
Number of subjects: 40
Study: 23345574

Group type: EXPERIMENTAL
Intervention: 12 months of prophylactic antibiotics
Number of subjects: 168

Group type: COMPARATOR
Intervention: Community managed exacerbations
Number of subjects: 168

Group type: COMPARATOR
Intervention: Hospital managed exacerbations
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Overall exacerbation rate
Number of subjects: 168

Group type: COMPARATOR
Intervention: Hospital-managed exacerbation
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Exacerbation rate in the first 2 years
Number of subjects: 168

Group type: COMPARATOR
Intervention: Weight z scores at 5 years of age
Number of subjects: 168
Study: 21199487

Group type: EXPERIMENTAL
Intervention: Dynamic testing with graduate prompt techniques
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no dynamic testing)
Number of subjects: 77
Study: 19726903

Group type: EXPERIMENTAL
Intervention: Public health center smoking cessation counseling program using the transtheoretical model
Number of subjects: 115

Group type: COMPARATOR
Intervention: Korean Ministry of Health & Welfare smoking cessation program
Number of subjects: 115
Study: 17887990

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/4.5 microg
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol DPI 160/4.5 microg
Number of subjects: 680

Group type: COMPARATOR
Intervention: Budesonide pMDI 200 microg
Number of subjects: 680
Study: 14871253

Group type: EXPERIMENTAL
Intervention: rFVIIa (90 microg/kg i.v.) given 3 h after idraparinux (7.5 mg s.c.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rFVIIa (90 microg/kg i.v.) given 1 week after idraparinux (7.5 mg s.c.)
Number of subjects: 12
Study: 11528604

Group type: EXPERIMENTAL
Intervention: Multidisciplinary behavioral treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 24
Study: 9806026

Group type: EXPERIMENTAL
Intervention: CIV IL-2
Number of subjects: 115
Study: 7702020

Group type: EXPERIMENTAL
Intervention: Fructose (50 g) added to a standard (40-g oral) fat load
Number of subjects: 11
Study: 2484836

Group type: EXPERIMENTAL
Intervention: Livingston's chemotherapy combined with isoprinosine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Livingston's chemotherapy with shortened treatment cycle (8 days) and isoprinosine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Livingston's chemotherapy (control group)
Number of subjects: 3
Study: 757241

Group type: EXPERIMENTAL
Intervention: Metal cannula
Number of subjects: 300

Group type: COMPARATOR
Intervention: Flexible plastic cannula
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both cannulas
Number of subjects: 300
Study: 31394955

Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 178

Group type: COMPARATOR
Intervention: Nasal prong
Number of subjects: 178
Study: 29925182

Group type: EXPERIMENTAL
Intervention: 5 F Tiger Ⅰ shaping technique
Number of subjects: 159

Group type: COMPARATOR
Intervention: 6 F Judkins and Amplatz catheters
Number of subjects: 159
Study: 27101815

Group type: EXPERIMENTAL
Intervention: Fulranumab 1mg (1mgQ4wk)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Fulranumab 3mg (3mgQ4wk)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Fulranumab 6mg loading dose followed by 3mg (6mgLD+3mgQ4wk)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Fulranumab 10mg (10mgQ4wk)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 24675714

Group type: EXPERIMENTAL
Intervention: High Protein/Low Glycemic Index (HP/LGI)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Low Protein/Low Glycemic Index (LP/LGI)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: High Protein/High Glycemic Index (HP/HGI)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Low Protein/High Glycemic Index (LP/HGI)
Number of subjects: 256
Study: 22169830

Group type: EXPERIMENTAL
Intervention: Lifestyle course in combination with physical activity (intervention group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Physical activity alone (control group)
Number of subjects: 99
Study: 20798560

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with bevacizumab (leucovorin, 5-fluorouracil plus irinotecan)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Chemotherapy alone (leucovorin, 5-fluorouracil plus irinotecan)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with bevacizumab
Number of subjects: 222

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 222
Study: 19177819

Group type: EXPERIMENTAL
Intervention: Eversion carotid endarterectomy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Conventional carotid endarterectomy
Number of subjects: 201
Study: 16213302

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg, three times a day, 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous ganciclovir (5 mg/kg, 2 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral and intravenous ganciclovir
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CMV infection
Number of subjects: 34
Study: 12769004

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10685331

Group type: EXPERIMENTAL
Intervention: GnRHa plus oral estriol 4 mg/day for 4 months (add-back group; n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Leuprolide acetate depot alone at a dose of 3.75 mg s.c. every month for 6 months (non add-back group; n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non add-back group
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GnRHa plus oral estriol add-back therapy
Number of subjects: 12
Study: 8763462

Group type: EXPERIMENTAL
Intervention: Lamisil (terbinafine) 250 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Itraconazole 200 mg/day
Number of subjects: 0
Study: 1811337

Group type: COMPARATOR
Intervention: Fish diet (200 g/d of lean Australian fish flesh)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fish + Oil diet (200 g/d of lean Australian fish flesh + 5 g/d fish oil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fish + Oil diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fish diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fish diet and Fish + Oil diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study: 6130658

Group type: EXPERIMENTAL
Intervention: Pindolol (0.4 mg i.v.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metoprolol (5 mg i.v.)
Number of subjects: 21
Study: 6740566

Group type: EXPERIMENTAL
Intervention: Heparin treatment (subcutaneous or intravenous)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Coumarin treatment
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Patients with recurrent thromboembolic episodes
Number of subjects: 98
Study: 30587933

Group type: EXPERIMENTAL
Intervention: Bbr alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fbt alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Svt alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bbr plus Fbt
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bbr plus Svt
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined administration of Bbr with Fbt and Svt
Number of subjects: 60
Study: 29451825

Group type: EXPERIMENTAL
Intervention: Social Cognition and Object Relations Scale-Global Rating Method (SCORS-G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 27251185

Group type: EXPERIMENTAL
Intervention: Cranberry beverage (240 mL/day)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 373
Study: 24864125

Group type: EXPERIMENTAL
Intervention: TIV followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: TIV followed by nonadjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Saline followed by AS03-adjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Saline followed by nonadjuvanted A(H1N1)pdm09 vaccine
Number of subjects: 133
Study: 22554673

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 249

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 249
Study: 20190704

Group type: EXPERIMENTAL
Intervention: Method C (Integran, a sheet-type absorbable topical collagen hemostat)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Method G (combined approach with TachoComb or PGA sheet fixed with fibrin glue)
Number of subjects: 72
Study: 17659194

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with CYP3A4-MET statins
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo with CYP3A4-MET statins
Number of subjects: 15603

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with non-CYP3A4-MET statins
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo with non-CYP3A4-MET statins
Number of subjects: 15603

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with atorvastatin
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo with atorvastatin
Number of subjects: 15603

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day with pravastatin
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo with pravastatin
Number of subjects: 15603
Study: 15821659

Group type: EXPERIMENTAL
Intervention: Sharp scissors and hemoclips (Group 3)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Electrocautery (Group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ultrasonic scalpel (Group 2)
Number of subjects: 90
Study: 12657846

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg intravenously every 12 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Troleandomycin (every 6 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11140216

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8666704

Group type: EXPERIMENTAL
Intervention: High-hypnotizable participants
Number of subjects: 2

Group type: COMPARATOR
Intervention: Simulators (low-hypnotizable control participants)
Number of subjects: 2
Study: 2064956

Group type: EXPERIMENTAL
Intervention: Daunorubicin (two doses on the first 2 days of induction)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Standard treatment without daunorubicin
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Treatment continued for 3 years
Number of subjects: 829

Group type: COMPARATOR
Intervention: Treatment stopped after 2 years
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Overall treatment (including all agents)
Number of subjects: 829
Study: 6367371

Group type: EXPERIMENTAL
Intervention: Atenolol 50-100 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Captopril 25-50 mg 3 times daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Captopril combined with hydrochlorothiazide (25-50 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol combined with hydrochlorothiazide (25-50 mg)
Number of subjects: 25
Study: 31778021

Group type: EXPERIMENTAL
Intervention: Cleanser with 5‐aminolevulinic acid and peptides
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic cleanser (control)
Number of subjects: 60
Study: 30744621

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Exercise plus diet
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Comparison between diet and exercise plus diet
Number of subjects: 243
Study: 28660421

Group type: EXPERIMENTAL
Intervention: Initiation of space closure 2-4 weeks after tooth extraction (arm A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Initiation of space closure ≥12 weeks after tooth extraction (arm B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Maxillary sites
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mandibular sites
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Severity of gingival invaginations
Number of subjects: 74
Study: 25226307

Group type: EXPERIMENTAL
Intervention: Squat Group (SG) - n = 10
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Take-off Group (TG) - n = 11
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 21
Study: 24395497

Group type: EXPERIMENTAL
Intervention: Transradial intervention (TRI) and bivalirudin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfemoral intervention (TFI) and unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI)
Number of subjects: 0
Study: 21465244

Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (CC)
Number of subjects: 14
Study: 18977464

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17112460

Group type: EXPERIMENTAL
Intervention: Chitosan-containing gum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control gum (without chitosan)
Number of subjects: 50